Genmab A/S (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Brokerages

Genmab A/S (NASDAQ:GMAB) has been assigned an average rating of “Moderate Buy” from the ten analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $45.20.

Several research firms recently commented on GMAB. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Wednesday, October 16th. BMO Capital Markets restated an “outperform” rating and issued a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Truist Financial lowered their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, September 9th. Redburn Atlantic assumed coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. Finally, Morgan Stanley restated an “equal weight” rating and set a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. raised its position in Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after purchasing an additional 544 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Genmab A/S by 123.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company’s stock worth $81,000 after buying an additional 1,787 shares during the period. Blue Trust Inc. increased its holdings in shares of Genmab A/S by 892.0% in the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after buying an additional 3,880 shares during the period. Headlands Technologies LLC lifted its stake in shares of Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after acquiring an additional 4,853 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. boosted its holdings in Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after acquiring an additional 478 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Up 1.6 %

GMAB stock opened at $21.50 on Monday. The stock has a 50-day simple moving average of $22.64 and a two-hundred day simple moving average of $25.63. Genmab A/S has a twelve month low of $20.34 and a twelve month high of $32.88. The firm has a market capitalization of $14.23 billion, a PE ratio of 20.87, a PEG ratio of 0.65 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The firm had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. During the same period in the prior year, the firm posted $0.47 EPS. On average, equities research analysts anticipate that Genmab A/S will post 1.3 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.